Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-19

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this experimental medicine study is to determine the extent to which different prime-boost combinations influence serum neutralising antibody breadth and associated B and T cells responses.

The investigators hypothesise that the different prime-boost model immunogen combinations will have differential impact on: the magnitude and breadth of induced serum neutralising antibodies; and the induced B- and T-cell responses in peripheral blood.

The investigators will investigate this by challenging the immune system of healthy adults with various model immunogens based on HIV-1 Env (ConM and ConS, with and without EDC stabilisation; Mos3.1, Mos3.2 and Mos3.3, and AMC011 and 763 SOSIP) in different prime-boost combinations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Modelling the Interaction Between Synthetic Model Immunogens and the Induced B and T Cell Repertoires.

NCT04046978

Virus Diseases

WITHDRAWN NA

Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

NCT06205056

Human Immunodeficiency Virus

RECRUITING PHASE1

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767

HIV-1-infection

RECRUITING PHASE1/PHASE2

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

NCT05471076

HIV-1-infection

ACTIVE_NOT_RECRUITING PHASE1

Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine

NCT01827397

- HIV

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One of the most effective arms of the human immune system is the ability of very low concentrations of antibody proteins to bind to viruses, bacteria and toxins and "neutralise" their activity or ability to infect. In contrast to cellular immunity, which may cause tissue destruction and pathology, antibody-mediated immunity can be very passive, while completely preventing infection. How antibodies bind their targets varies enormously, ranging from unhelpful "blocking" antibodies or narrowly focussed neutralising antibodies, to highly protective "broadly neutralising" antibodies (bNAbs) that can neutralise a wide range of strains of the same pathogen. Such bNAbs are especially sought after in virus infections such as HIV, influenza and others where the virus mutates to evade immune responses that are too narrow or focussed. Antibodies arise when an "immunogen" (an immunogen is anything that induces an immune response, typically a foreign protein) is taken up by the immune system and shown to white blood cells - T and B cells - by specialised immune cells. In some cases the T and B cells bind the immunogens to receptors on their surface, triggering an immune response in which T cells "help" B cells to manufacture specific antibodies. The events around how the protein is processed into manageable pieces, shown to the T and B cells, and the pattern of chemical signals produced by the immune cells is highly complex, but eventually determines how broad the antibody response will be (its breadth). For infections like HIV and influenza, decades of research and clinical vaccine trials have had limited or no success. To take HIV as an example, investigators have an almost complete lack of understanding of how immunogens interact with the naive human B cell receptor (BCR) repertoire and the pathways required to induce bNAbs during an infection or after an immunisation. Animal models have failed as the naïve, germline encoded, B cell antibody receptor repertoires of non-human species are sufficiently different from those of humans to render design and selection of vaccine based on non-human species problematic. Additionally, bNAbs isolated from HIV-1-infected individuals have structural features that occur rarely or not at all in other mammals, such as unusually long loop-binding regions (CDRH3 loops) required to penetrate past glycans on the surface of the envelope spike that shield key neutralising epitopes. There is therefore a critical need to better understand, in human experimental medicine models of immune challenge, how immunogens and B/T cells interact in the development of protective bNAb anti-viral responses.

The approach by the investigators to resolving this impasse is to challenge the human immune system with rationally-designed model immunogens to determine the structural and other characteristics required to drive human B cell antibody responses towards neutralisation breadth. The investigators have selected HIV as an experimental model as there is a reasonable understanding about the specificity and function of anti-HIV bNAbs, as well as an urgent need to identify novel immunisation approaches following decades of failed or poorly successful trials. There is also a huge database of safety using HIV proteins as immunogens, and the technological expertise to design and manufacture HIV viral proteins. Assays for HIV neutralising activity are also well established in the study team's laboratories. Although focussed on HIV, the investigators' findings will be applicable to other viral infections.

The model immunogens proposed in the experimental medicine studies are unlikely to be suitable as vaccines, and any clinical development would require iterative cycles of design refinement and development based on immunological insights gleaned from these experimental investigations. Therefore, the focus is on in-depth characterisation of the elicited immune response to rationally-designed model immunogens that may inform the design process of actual vaccines. This experimental medicine approach is only now possible due to unprecedented progress in abilities to study the human immune system and to obtain complete information on immune responses to vaccination, since performing research on the human immune system is now almost as easy as it has been in mice. The main focus of this study will be to determine which of the design strategies is able to prime human germline (naive) B cells and drive antibody responses towards induction of neutralising antibody breadth.

The investigators' range of model immunogens will be based on the envelope (Env) glycoprotein of HIV-1, which is the only target of neutralising antibodies, and therefore the only virally-encoded immunogen relevant for induction of such antibodies by immunisation. To ensure reproducibility of results and the highest level of volunteer safety, all immunogens will be manufactured under cGMP, using techniques applied to vaccine immunogens.

Env has extensive amino acid variation, structural and conformational instability, and immunodominance of hypervariable regions. The study team designed soluble immunogens that closely mimic the native viral trimer in situ, but that incorporate design strategies that may alter the intrinsic viral immune evasion mechanisms. Env is made up of three identical complexes (trimers) each of which contains two molecules, gp120 and gp41 that can be modified to make a soluble molecule called gp140, upon which the investigators' immunogens are based. Investigators have developed model consensus gp140 Env trimers (consensus of all global strains) designed to prime B cell responses to common epitopes represented in all HIV-1 subtypes. Investigators have utilised two design strategies to stabilise these in a native-like conformation: ConM SOSIP and ConS UFO.

The ConM SOSIP trimer includes novel mutations that include the incorporation of a disulphide linkage between the gp120 and gp41 ectodomain (making up gp140) which prevents their disassociation into monomer subunits. The ConS UFO includes a short flexible amino-acid linker to tether the gp120 and gp41 subunits together as an alternative strategy to prevent dissociation of the Env trimer. The investigators wish to test both designs to determine the effect on B cell repertoire. To further stabilize global architecture, the investigators employed an EDC crosslinking approach that has been shown to conserve bNAb epitopes, reduce non-antiviral antibody responses, and enhance overall immunogen stability. Thus, in Part 1 of this study the investigators will test EDC ConM SOSIP and EDC ConS UFO versions in parallel.

A critical adjunct to the investigators' consensus-based model design is to use a cocktail of three mosaic gp140 Env trimers as a boost (Part 2) to overcome the immunodominance of hypervariable regions of Env and to determine whether this will focus antibody responses towards conserved neutralisation epitopes. While designed using computer algorithms, these mosaics represent authentic Env structures that are fully functional and native in their conformation. The investigators' novel designs aim to eliminate unwanted immunodominant antibody responses and focus B cells towards highly conserved supersites of vulnerability on Env, with particular emphasis on quaternary bNAb epitopes. The extent to which these different strategies may induce neutralising breadth, and the identification of the mechanisms and drivers involved, can only be determined empirically through human immunogen challenge studies.

Two HIV-1 envelope sequences (AMC011 SOSIP and 763 SOSIP) will also be used as immunogens in some of the study groups. The EAVI2020 programme has found these to be associated with the early induction of broadly neutralising antibodies. The sequences were identified from two HIV infected individuals who displayed HIV neutralisation breadth early in infection (less than 12 months). This is unusual as typically neutralisation breadth is only seen to develop in \< 5% of subjects and only after a period of more than 2 years. The investigators seek to test the hypothesis that these two envelope sequences may display unique potential to prime and/or drive the induction of broadly neutralising antibody responses in HIV negative healthy volunteers. To test this hypthesis the EAVI2020 consortium has manufactured stabilised versions of these two envelope proteins to GMP. These will be used alone and in various combinations with consensus and mosaic immunogens to determine the extent to which they can drive the induction of broadly neutralising antibodies. Responses to these unique envelope sequences will be compared and contrasted to the consensus and mosaic immunogens evaluated in other study groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1-infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

This is a single-blind study with volunteers being randomised into five groups of n=10 (Groups A-E) and eight groups of n=8 (Groups F-M), stratified by gender

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Volunteers will be blinded to their treatment regimes, and laboratory teams undertaking immunological analysis will be blinded to group and dosing regimen to prevent in-house analysis bias. The clinical team will remain un-blinded throughout.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: ConM SOSIP and Mosaic SOSIPs

ConM SOSIP 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months

Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group B: EDC ConM SOSIP and Mosaic SOSIPs

EDC ConM SOSIP 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months

Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only

Group Type ACTIVE_COMPARATOR

EDC ConM SOSIP

Intervention Type BIOLOGICAL

Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group C: ConS UFO and Mosaic SOSIPs

ConS UFO 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months

Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only

Group Type ACTIVE_COMPARATOR

ConS UFO

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group D: EDC ConS UFO and Mosaic SOSIPs

EDC ConS UFO 100mcg Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months

Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only

Group Type ACTIVE_COMPARATOR

EDC ConS UFO

Intervention Type BIOLOGICAL

Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group E: ConS UFO and ConM SOSIP and Mosaic SOSIPs

ConS UFO 100mcg Intramuscular injections into the left or right arm Administered at 0 and 3 months

ConM SOSIP 100mcg Intramuscular injection into the left or right arm Administered at 6 months

Mosaic SOSIPs (Mos3.1 + Mos3.2) 100mcg (2x50mcg) Intramuscular injections into the left or right arm Administered at 12 months only

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

ConS UFO

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group F: Mosaic SOSIPs and ConM SOSIP and ConS UFO

Mosaic SOSIP Mos3.1 100mcg Intramuscular injection into the left or right arm Administered at 0 months

Mosaic SOSIP Mos3.2 100mcg Intramuscular injection into the left or right arm Administered at 2 months

Mosaic SOSIP Mos3.3 100mcg Intramuscular injection into the left or right arm Administered at 4 months

ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

ConS UFO

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group G: Mosaic SOSIPs and ConM SOSIP and ConS UFO

Mosaic SOSIP Mos3.2 100mcg Intramuscular injection into the left or right arm Administered at 0 months

Mosaic SOSIP Mos3.1 100mcg Intramuscular injection into the left or right arm Administered at 2 months

Mosaic SOSIP Mos3.3 100mcg Intramuscular injection into the left or right arm Administered at 4 months

ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

ConS UFO

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group H: Mosaic SOSIPs and ConM SOSIP and ConS UFO

Mosaic SOSIP Mos3.3 100mcg Intramuscular injection into the left or right arm Administered at 0 months

Mosaic SOSIP Mos3.2 100mcg Intramuscular injection into the left or right arm Administered at 2 months

Mosaic SOSIP Mos3.1 100mcg Intramuscular injection into the left or right arm Administered at 4 months

ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

ConS UFO

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group I: Mosaic SOSIPs and ConM SOSIP and ConS UFO

Mosaic SOSIPs (Mos3.1 + Mos3.2 + Mos3.3) 100mcg (3x33mcg) Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months

ConM SOSIP + ConS UFO 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 6 months

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

ConS UFO

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group J: 763 SOSIP

763 SOSIP 100mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months

Group Type ACTIVE_COMPARATOR

763 SOSIP

Intervention Type BIOLOGICAL

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group K: AMC011 SOSIP

AMC011 100mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months

Group Type ACTIVE_COMPARATOR

AMC011 SOSIP

Intervention Type BIOLOGICAL

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group L: 763 SOSIP and AMC011 SOSIP

763 SOSIP and AMC011 50mcg + 50mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months

Group Type ACTIVE_COMPARATOR

763 SOSIP

Intervention Type BIOLOGICAL

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

AMC011 SOSIP

Intervention Type BIOLOGICAL

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Group M: 763 SOSIP and AMC011 SOSIP and ConM SOSIP and Mosaic SOSIPs

763 SOSIP and AMC011 SOSIP and ConM SOSIP and Mos3.1 and Mos3.2 SOSIPs each at 20mcg Intramuscular injections into the left or right arm Administered at 0, 2 and 4 months

Group Type ACTIVE_COMPARATOR

ConM SOSIP

Intervention Type BIOLOGICAL

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Mosaic SOSIPs

Intervention Type BIOLOGICAL

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

763 SOSIP

Intervention Type BIOLOGICAL

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

AMC011 SOSIP

Intervention Type BIOLOGICAL

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ConM SOSIP

Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention Type BIOLOGICAL

EDC ConM SOSIP

Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention Type BIOLOGICAL

ConS UFO

Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle

Intervention Type BIOLOGICAL

EDC ConS UFO

Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention Type BIOLOGICAL

Mosaic SOSIPs

Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention Type BIOLOGICAL

763 SOSIP

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention Type BIOLOGICAL

AMC011 SOSIP

HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male and female volunteers aged between 18 and 55 years.
2. Available for ALL follow-up visits for the duration of the study.
3. Entered and clearance obtained from The Over volunteering Prevention System (TOPS) database (to avoid impact of any co-administered investigational products or treatments on our outcomes).
4. Women of childbearing potential willing to use a highly effective method of contraception for the duration of the study until a minimum of 12 weeks after the final injection. Periodic abstinence (calendar, symptothermal and post-ovulation methods) and withdrawal are not acceptable methods of contraception.
5. Willing and able to give written informed consent.

Exclusion Criteria

1. History of any medical, psychological or other condition, clinically significant laboratory result at screening, or use of any medications which, in the opinion of the investigators, would interfere with the study objectives or volunteers safety.
2. Any history of angioedema.
3. History of urticaria deemed significant by the Chief Investigator.
4. HIV-1 or HIV-2 antibody positive or indeterminate upon screening, or history of receipt of Env-based HIV immunogens (which would render the volunteers non-naive to the model immunogens).
5. Unable to read and/or speak English to a fluency level adequate for the full comprehension of study procedures and consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes